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length of stay (LOS) and costs. Results were projected to the national level. Gener-
alized linear models were used for the analysis. Covariates included the baseline
patient-level surgical risk factors and hospital characteristics. RESULTS: SSI inci-
dence was highest among colon surgery [12.0%, 95%CI:11.78-12.2%0)] and CABG
[6.1%; 95%CI:5.88-6.2%)] cases, and lowest among C-section [0.3%; 95%CI:0.28-
0.31%)] and vaginal hysterectomy [0.16%; 95%CI:0.13-0.2%)] cases. The projected
national rates captured by Premier database were similar to the rates reported by
the National Health Safety Network reported rates. Among all surgical procedures,
health resource use associated with CABG and colon surgery cases were most
affected by SSI. SSI resulted on an average 10.58 [SD 2.78; (95%CI:10.56-10.60)] days
and 9.72 [SD 3.43; (95%CI:9.70-9.74)] days of additional LOS and $38,796 [SD $8,555;
(95%CI:$38,741-$38,850)] and $19,349 [SD $5,720; (95%CI:$19,315-$19,383)] of addi-
tional costs in CABG and colon procedures respectively. CONCLUSIONS: Despite
rise in infection control practices postoperative SSIs continue to remain associated
with significant increases in LOS and hospitalization costs.
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OBJECTIVES: Approximately 3% of the global population is infected with the hep-
atitis C virus. 20% of the patients will develop cirrhosis within 20 years of infection,
and these patients have a 1% to 5% risk per year of developing hepatocellular
carcinoma (HCC). Standard treatment for hepatitis C is pegylated interferon com-
bined with ribavirin. The objective of this study was to obtain an understanding of
the resource utilisation and costs associated with chronic hepatitis C in Sweden.
METHODS: A literature review was conducted to identify resource utilisation and
costs of chronic hepatitis C in Sweden. The MEDLINE, EMBASE, NHS EED and Co-
chrane CCTR databases were searched. To validate the results of the literature
review and fill gaps in the evidence base, interviews were conducted with eight
clinicians and one nurse specialised in the areas of infection, gastroenterology or
transplantation medicine. The Skåne price list was primarily used to obtain the
unit costs. RESULTS: Twelve publications were relevant for inclusion in the review.
There was a lack of resource utilisation data for certain disease stages, primarily
decompensated cirrhosis and HCC, and for updated unit costs, in these publica-
tions. Also, no studies reported indirect costs associated with chronic hepatitis C in
Sweden. The pooled data from the literature review and the interviews indicated a
direct cost per year of EUR 300 for mild disease, EUR 400 for moderate disease, EUR
900 for compensated cirrhosis, EUR 13,000 for decompensated cirrhosis, EUR 20,000
for HCC and EUR 120,000 for liver transplantation (including one-year follow up).
CONCLUSIONS: Chronic hepatitis C is associated with high rates of health care
utilisation. The driver of the direct medical costs is the management of long-term
consequences including cirrhosis, HCC and liver transplantation. More efficient
therapies with higher cure rates could potentially result in long-term cost savings
by reducing severe complications.
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OBJECTIVES: Treatment of chronic hepatitis C infection is well established and will
be expanded to triple treatment with new drugs like hepatitis C virus (HCV) pro-
tease inhibitors in Germany in fall 2011. Costs related to the current HCV guidelines
will be a basis for further health economic analyses needed for pricing strategies
but are not available yet. The aim of this study is to analyse the costs associated
with diagnosis, treatment and monitoring of HCV infected patients according to
the 2010 German S3-consensus guideline considering HCV genotype and length of
therapy. METHODS: Patients with chronic HCV infection were divided in patients
with 1) normal transaminases; 2) elevated transaminases; 3) compensated cirrho-
sis; and 4) decompensated cirrhosis. Direct costs according to the actual 2010 HCV
German guideline were analysed for basic diagnostic procedures, monitoring and
treatment for patient groups 1-3. Costs were modelled according to treatment
duration (16 to 72 weeks) depending on the sustained viral response and HCV
genotype. Costs were calculated according to the German outpatient fee scale
EBM-2010. RESULTS: Costs for basic diagnostics including determination of HCV
genotype and diagnosis of potential hepatic comorbidities accounted for €401 per
patient. Monitoring costs accounted for €596 – €1173 depending on length of ther-
apy. Pharmaceutical costs accounted for the largest part of the costs (€7,709 –
€34,692). The total costs of a 16-week treatment including basic diagnostics, mon-
itoring and pharmaceutical costs accounted for €8,706, €12,734 for a 24-week treat-
ment, €24,529 for a 48-week treatment and €36,266 for 72-week treatment.
CONCLUSIONS: State of the art and guideline cost evaluation for treatment of HCV
infection show high costs for optimal and viral response guided therapy. These
data can be used for further investigation of real life costs and costs of new triple
treatment strategies in HCV treatment.
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OBJECTIVES: The cost analysis of ten schemes antibiotic therapy (AT) in patients
with acute peritonitis was conducted. These schemes are recommended by the
Clinical Protocol of acute peritonitis treatment (MHO of Ukraine, order 1297,
02.04.2010) for use in practice. METHODS: The schemes of antibacterial therapy
are: I – ertapenem (1,0 gr intravenously (iv.) 1 time/day); II – cefotaxim (1,0 gr im. 3
times/day and metronidazol 100 ml (sol. 0,5%) iv. 2 times/day); III – amoxicillin
clavulanate (1,2 gr 3 times/day); IV – moxifloxacin (400 mg 1 time/day); V – levo-
floxacin (500 mg iv. 1 time/day and metronidazol 100 ml (sol.0,5%) iv. 2 times/day);
VI – cefepim (2,0 gr iv. 2 times/day and metronidazol 100 ml (sol.0,5%) iv. 2 times/
day; VII – cefoperazone sulbactam (2,0 gr 3 times/day); VIII – meropenem (500 mg
iv. 4 times/day); IX – imipenem  cilastatin (500 mg/500 mg iv. 4 times/day); X –
ciprofloxacin 400 mg iv. and metronidazol 100 ml (sol.0,5%) iv. 2 times/day. Three
variants for each scheme were calculated: the schemes with original drugs, the
schemes with generics and the schemes with ukrainian generics. Doses and dura-
tion of AT were calculated in accordance with the Clinical Protocol of acute perito-
nitis treatment. RESULTS: The costs range of treating one patient with acute peri-
tonitis with original drugs is 3891 UAN (scheme I) - 7994 UAN (scheme VI). The costs
range with generics of ukrainian production is 1924 UAN (scheme V) - 5413 UAN
(scheme VIII) (1 EUR 11,65 UAN).CONCLUSIONS: The costs of treatment schemes
for patients with acute peritonitis with use of less expensive generic drugs are not
always cheaper than the costs of original drugs using. The optimal schemes for
treatment of patients with acute peritonitis were selected.
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OBJECTIVES: Seventy-nine percent of the skin and soft tissue infections (SSTI) are
caused by staphylococcus aureus, from which 1/3 is methicilin-resistant staphylo-
coccus aureus (MRSA). This study aims to compare SSTI-MRSA treatment costs
with linezolid versus branded and generic vancomycin under the Brazilian public
payer perspective.METHODS:A cost comparison study was performed to compare
linezolid versus generic and branded vancomycin. As supported by clinical studies,
overall treatment duration of 15 days with linezolid and 14 days with vancomycin
was considered, using PO linezolid after a minimum 4-days cycle of IV infusion
while vancomycin (1g bid) was entirely IV. A decision-tree model simulated SSTI-
MRSA treatment assuming linezolid (600mg bid) IV can be switched to PO after
4-days and patients can be discharged if PO is implemented at physician discretion.
Length of stay (LOS) and IV linezolid duration were ranged in one-way sensitivity
analysis. Only direct medical costs were included in the analysis (hospital charges,
medical visits, medical supplies and drug acquisition costs) and unit costs were
obtained from Brazilian official price lists (2010 USD values). RESULTS: The lin-
ezolid scheme with 4-days IV (LOS4 days) and 11-days PO resulted in overall costs
per patient of 2,540 USD, while branded and generic vancomycin exhibited 3466
USD and 3663 USD, respectively. The incremental cost of vancomycin-treated pa-
tients was driven by hospital daily charges, responsible for over 60% of the overall
vancomycin costs. One-way sensitivity analysis revealed cost-savings for linezolid
up to LOS9 days, with overall costs per patient ranging from 2540-4548 USD even
if IV therapy was maintained throughout the inpatient period (LOS15 days).
CONCLUSIONS: Linezolid exhibited a cost-saving profile over branded or generic
vancomycin for the treatment of SSTI-MRSA under the Brazilian public payer per-
spective. This economic benefit was a direct result of potential early discharge of
patients receiving PO linezolid.
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OBJECTIVES: SARPAM is a programme, designed to ensure the improvement of
access to quality essential medicines in SADC. An economic appraisal was under-
taken from a societal perspective to assess the economic feasibility of SARPAM’s
implementation. The evaluative framework considered elements linked to im-
proved access to quality medicines which included regional procurement of ARVs.
The objective was to report the positive impact of this initiative on access to health
care. METHODS: Direct health care costs were estimated as the incremental in-
vestment needed to effectively implement regional cooperation processes over a 4
year period. Direct healthcare benefits were defined as the “negative costs” incurred
due to monetary savings and rational drug use. These savings were based on the
well-established advantages of regional procurement cooperation. Indirect health
care benefits were estimated using the Human Capital Approach. RESULTS: In
total, an investment of US$14 million in SARPAM (discounted at a rate of 4.5%) over
a four-year period will result in overall benefits of between US$20 million to US$38
million. The resultant benefit-cost ratio ranges from 1.40: 1 to 2.72: 1. In terms of
HIV/AIDS in South Africa in particular, the analysis estimated a potential maximum
incremental benefit of US$147 million which could treat an additional 757,000 pa-
tients with first line treatment. These results confirm that major benefits might be
derived from the SARPAM programme, including a regional procurement cooper-
ation intervention of ARVs. CONCLUSIONS: There is compelling evidence that the
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